CLINICAL PROFILE AND DRUG THERAPY OF VARIOUS LIVER DISEASES PROSPECTIVE OBSERVATIONAL STUDY
Main Article Content
Keywords
Clinical profile, Complications, Drug therapy, Social habits
Abstract
Liver disease is the tenth most common cause of death in India as per the WHO. The liver affects everyone in five Indians. Clinical profile plays a vital role in assessing the health conditions of a patient, based on the severity of the disease appropriate drug therapy will be recommended. The study's main objective was to determine the clinical profile and drug therapy of various liver diseases. It was a prospective observational study carried out in the medical ward of a tertiary care hospital in south India over a period of 6 months. A total of 150 patients were included in the study, out of that 142 patients were males and 8 were females. The study demonstrated the social habits, clinical profile, complications associated with liver disease, and the drug therapy prescribed for the patients. To get more insightful information further multi-centred studies are required to be conducted to draw the best results on prescribing patterns of liver disease in the Indian population.
References
2. Sivakrishnan S. Liver diseases overview. World journal of pharmacy and pharmaceutical science, 2019;8(1):1385-1395.
3. Rudler, M., Weiss, N., Bouzbib, C., &Thabut, D. (2021, May). Diagnosis and Management of Hepatic Encephalopathy. Clinics in Liver Disease, 2021;25(2):393–417.
4. Ray, G. Management of liver diseases: Current perspectives. World Journal of Gastroenterology, 2022;28(40):5818–5826.
5. Desalegn, H., Aberra, H., Berhe, N., Mekasha, B., Stene-Johansen, K., Krarup, H., Pereira, A. P., Gundersen, S. G., & Johannessen, A. (2018, December). Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Medicine, 2018;16(1).
6. Chen, H. L., Wu, S. H., Hsu, S. H., Liou, B. Y., Chen, H. L., & Chang, M. H. Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases. Journal of Biomedical Science,2018;25(1).
7. David S, and Hamilton JP. Drug-induced liver injury. NIH Public Access, 2010;6(1):73- 80.
8. Asrani SK, Devarbhavi H, Eeton J, Kamath PS. The burden of liver diseases in the world. J Hepatol,2023;79(2):516-537.
9. Cheemerla H, and Balakrishnan M. Global epidemiology of chronic liver diseases. Clin Liver Dis (Hoboken) 2021;17(5):365-370.
10. Textbook of Clinical Pharmacy and therapeutics-IV edition by Catewhittlesea, Karen Hodson.
11. Arshad, M. ., Asif, H., John, A., & Pasha, M. O. Chronic Liver Disease and its Complications. MARKHOR (The Journal of Zoology),2020;1(1):3–7.
12. Toniutto P, Special Issue “New Therapies of Liver Diseases”. J. Clin. Med. 2022; 11(7):1798.
13. Kemas AM, Youhanna S & Volker M. Lauschke (2022) Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development, Expert Review of Precision Medicine and Drug Development, 2022;7(1):39-49.
14. Thapa BR, Walia A. Liver function tests and their interpretation. Indian J Pediatr. 2007;74(7):663-671.
15. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, Mackie A, Mitchell-Thain R, Sennett K, Sheron NC, Verne J, Walmsley M, Yeoman A. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6-19.
16. Alkhouri N, Aggarwal P, Le P, Payne J, Sakkal C, Polanco P, Harrison S, Noureddin M. Simple diagnostic algorithm identifying at-risk non-alcoholic fatty liver disease patients needing specialty referral within the United States. World J Hepatol, 2022; 14(8):1598- 1607.
17. Kumar S. Overview of acute viral hepatitis. MSD, 2022.
18. Sivakrishnan S. Liver diseases an overview, World Journal of Pharmacy and Pharmaceutical Sciences, 2019;8(1)1385-1395.
19. Das J. Liver disease pathophysiology. Pharmaceutical journal, 2011.
20. Huma S, and Fatima ON. Prescribing Pattern of Drugs Used in Chronic Liver Disease with Co Morbid Conditions and Assessment of Severity using MELD Score: A Prospective Observational Study. Journal of Drug Delivery & Therapeutics. 2020; 10(5):19-24.
21. Gao B, and Bataller R. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets, Gastroenterology. 2011;141(5):1572–1585.
22. Onofrio FQ, Hirschfield GM. The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. Clinical Liver Disease. 2020 Mar;15(3):110-114.
23. Corrigan M, Hirschfield GM, Oo YH, Adams DH. Autoimmune hepatitis: an approach to disease understanding and management. Br Med Bull. 2015;114(1):181-191.
24. Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017;5(2):138-147.
25. Iwakiri Y. Pathophysiology of portal hypertension. Clinics in Liver Disease. 2014;18(2):281-291.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. G. Baby Sreshta
Assistant Professor, Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tirupati, Andhra Pradesh, India
K. Chandu priya
Pharm D interns, Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tirupati, Andhra Pradesh, India
B. Jaya sree
Pharm D interns, Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tirupati, Andhra Pradesh, India
G. Soumya
Pharm D interns, Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tirupati, Andhra Pradesh, India
C. Likhith
Pharm D interns, Department of Pharmacy Practice, Sri Padmavathi School of Pharmacy, Tirupati, Andhra Pradesh, India